Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Corvus Pharmaceuticals (CRVS) Invested Capital (2016 - 2026)

Corvus Pharmaceuticals' Invested Capital history spans 12 years, with the latest figure at $240.7 million for Q1 2026.

  • Quarterly Invested Capital rose 387.95% to $240.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $240.7 million through Mar 2026, up 387.95% year-over-year, with the annual reading at $61.2 million for FY2025, 87.93% up from the prior year.
  • Invested Capital came in at $240.7 million for Q1 2026, up from $61.2 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $240.7 million in Q1 2026 to a low of $12.4 million in Q3 2024.
  • The 5-year median for Invested Capital is $51.2 million (2024), against an average of $65.0 million.
  • Year-over-year, Invested Capital plummeted 71.98% in 2024 and then soared 478.35% in 2025.
  • Corvus Pharmaceuticals' Invested Capital stood at $56.1 million in 2022, then crashed by 31.06% to $38.7 million in 2023, then decreased by 15.81% to $32.6 million in 2024, then soared by 87.93% to $61.2 million in 2025, then soared by 293.23% to $240.7 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Invested Capital are $240.7 million (Q1 2026), $61.2 million (Q4 2025), and $71.8 million (Q3 2025).